1. Scrip
  2. >>Business
  3. >>Deals

Who next in antibiotic M&A gold rush?

 
• By Eleanor Malone

Shares in companies engaged in antibiotic development basked in the reflected glow of Merck & Co's just announced $9.5bn takeout deal for Cubist Pharmaceuticals (scripintelligence.com, 9 December 2014). This acquisition follows hot on the heels of Actavis's $675-820m purchase agreement for fellow antibiotics player Durata Therapeutics (scripintelligence.com, 7 October 2014), and is only the most ostentatious example of a deal-making trend that has been gathering pace over the past year or so.

Shares in companies engaged in antibiotic development basked in the reflected glow of Merck & Co's just announced $9.5bn takeout deal for Cubist Pharmaceuticals (scripintelligence.com, 9 December 2014). This acquisition follows hot on the heels of Actavis's $675-820m purchase agreement for fellow antibiotics player Durata Therapeutics (scripintelligence.com, 7 October 2014), and is only the most ostentatious example of a deal-making trend that has been gathering pace over the past year or so.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Deals

Novartis Gains Further Renal Territory With Regulus Acquisition

 
• By Alaric DeArment

The San Diego biotech’s lead product candidate is an antisense oligonucleotide-based therapy slated to enter Phase III development in the third quarter.

GSK Chief Optimistic About BD Despite Volatile Environment

 
• By Kevin Grogan

Emma Walmsley tells Scrip that the "biotech market is under a certain degree of pressure," so reasonably priced deals are available.

In Brief: Ferrer Signs Deal For Prilenia’s Pridopidine In Europe

 
• By Sushmita Panda

The companies will co-develop the drug for additional indications beyond Huntington’s disease, while Prilenia retains rights in key global markets.

UPDATED: Merck KGaA Seals SpringWorks Buy

 
• By Kevin Grogan

The German group is paying $3.9bn to get hold of the US firm and its two approved products.

More from Business

GSK Chief Optimistic About BD Despite Volatile Environment

 
• By Kevin Grogan

Emma Walmsley tells Scrip that the "biotech market is under a certain degree of pressure," so reasonably priced deals are available.

Pfizer CEO Bourla ‘Cautiously Optimistic’ About Tariffs, Pricing Policies

 
• By Mandy Jackson

Bourla said the pharma industry may be able to negotiate productive solutions to Trump tariff and drug pricing concerns. He asserted anti-science views are not shared by all in the administration.

Abeona Sets $3.1m Price For Rare Skin Disorder Gene Therapy

 
• By Joseph Haas

Abeona plans to offer an outcomes-based payment model for Zevaskyn, which likely will see complementary use with Krystal’s Vyjuvek in recessive dystrophic epidermolysis bullosa patients.